Table 3.
Treatment characteristics.
| Tumor Characteristics | N (%) | |
|---|---|---|
| 26Gy/5Fr/1w | 28.5Gy/5Fr/5ws | |
| Surgery | ||
| Quad/Lump | 5 (8.5) | 9 (81.8) |
| Quad/Lump + SLNB | 54 (91.5) | 0 (0.0) |
| Quad/Lump + SLNB + AD | 0 (0.0) | 2 (18.2) |
| Surgical margins | ||
| Positive or ‘close’ | 0 (0.0) | 0 (0.0) |
| Negative | 54 (91.5) | 11 (100.0) |
| NA | 5 (8.5) | 0 (0.0) |
| Adjuvant endocrine therapy | 50/59 (84.7) | 7/11 (63.6) |
| Tamoxifene | 6 (12.0) | 0 (0.0) |
| Aromatase inhibitors | 44 (88.0) | 6 (85.7) |
| LH-RH analogue + Exemestane | 0 (0.0) | 1 (14.3) |
| Adjuvant systemic therapy | 9/59 (15.3) | 0/11 (0.0) |
| EC + Weekly taxol | 3 (33.3) | 0 (0.0) |
| AC + Weekly taxol | 1 (11.1) | 0 (0.0) |
| TC + Weekly taxol | 1 (11.1) | 0 (0.0) |
| Weekly taxol | 3 (33.3) | 0 (0.0) |
| TC | 1 (11.1) | 0 (0.0) |
| Primary systemic therapy | 6/59 (10.2) | 0/11 (0.0) |
| EC + Weekly taxol | 4 (66.7) | 0 (0.0) |
| AC + Weekly taxol | 1 (16.7) | 0 (0.0) |
| CBDCA + Weekly taxol | 1 (16.7) | 0 (0.0) |
| HER2-blockade | 8/59 (13.6) | 0/11 (0.0) |
| Neoadjuvant | 3 (37.5) | 0 (0.0) |
| Adjuvant | 8 (100.0) | 0 (0.0) |
Legend: N°, number; Fr, fractions; w, week; ws, weeks; NA, not available; SLNB, sentinel lymph node biopsy; AD, axillary dissection; LH-RH, luteinizing hormone-releasing hormone; EC, epirubicin-cyclophosphamide; AC, adriamycin-cyclophosphamide; TC, taxotere-cyclophosphamide; CBDCA, carboplatin; HER2, Human Epidermal Growth Factor Receptor 2.